Article
Pharmacology & Pharmacy
Se-Eun Kim, Ho-Sung Jeon, Tae-Hwa Go, Jung-Hee Lee, Jun-Won Lee, Young Jin Youn, Byeong-Keuk Kim, Hyung Joon Joo, Do-Sun Lim, Kiyuk Chang, Yongwhi Park, Young Bin Song, Jung-Won Suh, Sang Yeob Lee, Jung Rae Cho, Ae-Young Her, Hyo-Soo Kim, Moo Hyun Kim, Eun-Seok Shin, Diana A. Gorog, Udaya S. Tantry, Paul A. Gurbel, Young-Hoon Jeong, Sung Gyun Ahn, PTRG DES Consortium Investigators
Summary: In Korean patients treated with DES, those with both high platelet reactivity and CYP2C19 gene loss-of-function alleles had the highest risk of adverse cardiac events. Combining platelet reactivity and CYP2C19 genotype can improve the prediction of patient outcomes.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2023)
Article
Cardiac & Cardiovascular Systems
Silvia Lee, Patricia P. Wadowski, Timothy Hoberstorfer, Constantin Weikert, Joseph Pultar, Christoph W. Kopp, Simon Panzer, Thomas Gremmel
Summary: The study found that hyperuricemia is associated with increased residual platelet reactivity in patients treated with clopidogrel and prasugrel, but not in those treated with ticagrelor.
CARDIOVASCULAR DRUGS AND THERAPY
(2021)
Letter
Medicine, General & Internal
John A. Bittl
Summary: The article discusses the preference for antithrombotic therapy in patients with acute coronary syndromes and the difference between preference and actual practice. It also mentions a new study, but does not explicitly state whether this new study can explain the discrepancy.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Hematology
Freek W. A. Verheugt, Kurt Huber, Peter Clemmensen, Jean-Philippe Collet, Thomas Cuisset, Felicita Andreotti
Summary: Antiplatelet therapy is crucial for preventing secondary ischemic heart disease. After PCI, temporary DAPT, which consists of aspirin and an oral P2Y12 receptor blocker, is recommended. However, long-term DAPT increases the risk of bleeding compared to aspirin monotherapy. To reduce bleeding, shorter DAPT duration or switching to P2Y12 inhibitor monotherapy have been suggested. This survey reviews the evidence and provides clinical guidance on the use of P2Y12 inhibitor monotherapy after DAPT cessation following PCI.
THROMBOSIS AND HAEMOSTASIS
(2023)
Article
Cardiac & Cardiovascular Systems
Yuichi Saito, Takeshi Nishi, Shinichi Wakabayashi, Yuji Ohno, Hideki Kitahara, Noritaka Ariyoshi, Yoshio Kobayashi
Summary: The ABCD-GENE score demonstrated significant diagnostic ability for HPR on clopidogrel in Japanese patients undergoing PCI, with consistent predictivity across a broad spectrum of patient populations.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Article
Medicine, General & Internal
Piotr Adamski, Malwina Baranska, Malgorzata Ostrowska, Wiktor Kuliczkowski, Katarzyna Buszko, Katarzyna Koscielska-Kasprzak, Bozena Karolko, Andrzej Mysiak, Jacek Kubica
Summary: This study compared the diurnal variability of platelet reactivity between patients receiving prasugrel and ticagrelor after acute myocardial infarction (AMI). The results showed that ticagrelor had greater diurnal variability in platelet aggregation compared to prasugrel, and there was a continuous increase of platelet inhibition after the morning maintenance dose. Both drugs provided adequate antiplatelet effect early after AMI.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Hiroyoshi Mori, Takuya Mizukami, Atsuo Maeda, Kazuki Fukui, Yoshihiro Akashi, Junya Ako, Yuji Ikari, Toshiaki Ebina, Kouichi Tamura, Atsuo Namiki, Ichiro Michishita, Kazuo Kimura, Hiroshi Suzuki
Summary: The 1-year rates of ischemic and bleeding events were similar in Japanese patients with AMI treated with prasugrel or clopidogrel.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Peripheral Vascular Disease
Yuichi Saito, Takeshi Nishi, Shinichi Wakabayashi, Yuji Ohno, Hideki Kitahara, Noritaka Ariyoshi, Yoshio Kobayashi
Summary: This study found that clinical and genetic factors have differential effects on P2Y12 inhibitor reactivity with clopidogrel and prasugrel in patients with coronary artery disease. The severity of these factors also has a different impact on high platelet reactivity (HPR).
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2022)
Article
Cardiac & Cardiovascular Systems
Kaoru Akimaru, Masashi Iwabuchi, Akio Ishida, Hiroki Uehara, Namio Higa, Masanori Kakazu, Minoru Wake, Taketoshi Maeda, Toshiki Maeda, Hisatomi Arima, Yusuke Ohya, Shinta Tokashiki, Hayashi Wakugawa, Ayane Miyagi, Shinya Shiohira, Satoshi Zaima, Tomohiro Shiohira, Yuichirou Toma, Hidekazu Ikemiyagi
Summary: Low-dose prasugrel achieves more consistent antiplatelet effects than clopidogrel in stable coronary artery disease (CAD) patients, irrespective of the metabolic phenotype.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Multidisciplinary Sciences
Christiane Franz, Lara Bender, Christoph Dorn, Thorsten Sichtermann, Jan Minkenberg, Maximilian Franko, Martin Wiesmann, Andrea Stockero, Omid Nikoubashman, Rebecca May, Hani Ridwan
Summary: Knowledge of platelet function in pigs and the effectiveness of antiplatelet therapy is important for the transferability of animal studies to humans. This study characterized the baseline platelet function of Aachen minipigs, compared it with Gottingen minipigs, and evaluated platelet inhibition after intravenous administration of acetylsalicylic acid (ASA). The results showed differences in baseline platelet function between the two pig breeds and immediate platelet inhibition after ASA administration in Aachen minipigs.
Article
Cardiac & Cardiovascular Systems
Tatsuya Fukase, Shinichiro Doi, Tomotaka Dohi, Takuma Koike, Ryota Nishio, Hidetoshi Yasuda, Mitsuhiro Takeuchi, Norihito Takahashi, Yuichi Chikata, Hirohisa Endo, Hiroki Nishiyama, Iwao Okai, Hiroshi Iwata, Shinya Okazaki, Hiroyuki Daida, Satoru Suwa, Tohru Minamino, Katsumi Miyauchi
Summary: This study aimed to evaluate the effects of -P2Y12 inhibitors on the -P2Y12 reaction unit (PRU) in the chronic phase after percutaneous coronary intervention (PCI). The results showed that clopidogrel treatment had a higher proportion of ischemic risk than prasugrel 2.5 mg. Prasugrel 2.5 mg also contributed to a decline in bleeding risk with dose reduction.
CARDIOVASCULAR DRUGS AND THERAPY
(2023)
Article
Medicine, General & Internal
Feng-Yu Kuo, Cheng-Han Lee, Wei-Ren Lan, Cheng-Huang Su, Wen-Lieng Lee, Yi-Chih Wang, Wei-Shiang Lin, Pao-Hsien Chu, Tse-Min Lu, Ping-Han Lo, Shuji Tsukiyama, Wei-Chen Yang, Li-Chung Cheng, Chien-Lung Huang, Wei-Hsian Yin, Ping-Yen Liu
Summary: This study investigated the impact of CYP2C19 genotype on the pharmacodynamics of Taiwanese ACS patients. The results showed that switching to low-dose prasugrel significantly reduced PRU levels and the proportion of HPR patients, especially in reduced metabolizers.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
(2022)
Article
Clinical Neurology
Kazunori Toyoda, Hiroshi Yamagami, Kazuo Kitagawa, Takanari Kitazono, Takehiko Nagao, Kazuo Minematsu, Shinichiro Uchiyama, Norio Tanahashi, Masayasu Matsumoto, Izumi Nagata, Masakatsu Nishikawa, Shinsuke Nanto, Toshiaki Shirai, Kenji Abe, Yasuo Ikeda, Akira Ogawa
Summary: The study found that both high mean systolic blood pressure levels and high visit-to-visit variability in blood pressure were significantly associated with the risk of recurrent stroke during long-term medication with either prasugrel or clopidogrel after a stroke, highlighting the importance of controlling hypertension regardless of the type of antiplatelet drugs.
Article
Biochemistry & Molecular Biology
Chih-Chien Hsu, Hao-Kai Chuang, Yu-Jer Hsiao, Yuan-Chi Teng, Pin-Hsuan Chiang, Yu-Jun Wang, Ting-Yi Lin, Ping-Hsing Tsai, Chang-Chi Weng, Tai-Chi Lin, De-Kuang Hwang, Ai-Ru Hsieh
Summary: In this study, a genome-wide association study was conducted on the largest Han population to date, leading to the identification of cataract-associated SNPs. Additionally, a polygenic risk score was developed to predict high-risk cataract individuals. These findings are of great significance for understanding the genetic basis of cataracts and predicting individual risk of developing cataracts.
Article
Medicine, Research & Experimental
Yonggu Lee, Young-Hyo Lim, Yongwhi Park, Jinho Shin
Summary: In this study, the safety, effectiveness, and treatment persistence of DAPT with clopidogrel, ticagrelor, and prasugrel were compared after PCI in the Korean population. Ticagrelor was associated with higher risk of bleeding, MACCE, and NACE compared to clopidogrel, whereas no significant differences were found between prasugrel and clopidogrel. Clopidogrel showed higher persistence and adherence rates in patients after PCI.
ADVANCES IN THERAPY
(2021)
Article
Pharmacology & Pharmacy
Joseph A. Jakubowski, Chunmei Zhou, David S. Small, Kenneth J. Winters, D. Richard Lachno, Andrew L. Frelinger, Jo Howard, Timothy G. Mant, Stipo Jurcevic, Christopher D. Payne
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2013)
Article
Pharmacology & Pharmacy
Christopher D. Payne, Mark A. Deeg, Melanie Chan, Lai Hock Tan, Elizabeth Smith LaBell, Tong Shen, David J. DeBrota
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2014)
Review
Pharmacology & Pharmacy
David S. Small, Nagy A. Farid, Christopher D. Payne, Christopher S. Konkoy, Joseph A. Jakubowski, Kenneth J. Winters, Daniel E. Salazar
CLINICAL PHARMACOKINETICS
(2010)
Article
Geriatrics & Gerontology
David S. Small, Rebecca E. Wrishko, C. Steven Ernest, Lan Ni, Kenneth J. Winters, Nagy A. Farid, Ying G. Li, Daniel E. Salazar, Christopher D. Payne
Article
Pharmacology & Pharmacy
David S. Small, Prajakti Kothare, Eunice Yuen, D. Richard Lachno, Ying G. Li, Kenneth J. Winters, Nagy A. Farid, Lan Ni, Joseph A. Jakubowski, Daniel E. Salazar, Vivian T. Thieu, Christopher D. Payne
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
(2010)
Article
Cardiac & Cardiovascular Systems
Joseph A. Jakubowski, Ying G. Li, David S. Small, Christopher D. Payne, Molly E. Tomlin, Junxiang Luo, Kenneth J. Winters
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2010)
Article
Cardiac & Cardiovascular Systems
Kyung-Sang Yu, Kyung Woo Park, Ronan P. Kelly, Namyi Gu, Christopher Payne, David S. Small, Hyunah C. Choi, Eiji Kawakatsu, Philippe Pinton
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2013)
Article
Pharmacology & Pharmacy
David S. Small, Nagy A. Farid, Christopher D. Payne, Govinda J. Weerakkody, Ying G. Li, John T. Brandt, Daniel E. Salazar, Kenneth J. Winters
JOURNAL OF CLINICAL PHARMACOLOGY
(2008)
Article
Pharmacology & Pharmacy
David S. Small, Ying G. Li, C. Steven Ernest, John H. April, Nagy A. Farid, Christopher D. Payne, Kenneth J. Winters, Shashank Rohatagi, Lan Ni
JOURNAL OF CLINICAL PHARMACOLOGY
(2011)
Article
Pharmacology & Pharmacy
Eunice Yuen, Ivelina Gueorguieva, Stephen Wise, Danny Soon, Leon Aarons
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
(2010)
Article
Cell Biology
Ying G. Li, Lan Ni, John T. Brandt, David S. Small, Christopher D. Payne, C. Steven Ernest, Shashank Rohatagi, Nagy A. Farid, Joseph A. Jakubowski, Kenneth J. Winters
Article
Neurosciences
Stephen Lowe, Robert Dean, Bradley Ackermann, Kimberley Jackson, Fanni Natanegara, Shelby Anderson, James Eckstein, Eunice Yuen, Mosun Ayan-Oshodi, Mary Ho, David McKinzie, Kenneth Perry, Kjell Svensson
PSYCHOPHARMACOLOGY
(2012)